Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22.
暂无分享,去创建一个
E. Braunwald | C. Cannon | D. Morrow | S. Murphy | P. Jarolim | E. Grandin | L. Ritterová | P. Jarolím | E Wilson Grandin | Christopher P Cannon | David A Morrow
[1] D. Sanoudou,et al. Regulation of adverse remodelling by osteopontin in a genetic heart failure model. , 2012, European heart journal.
[2] P. Muntendam,et al. Galectin-3 in heart failure: high levels are associated with all-cause mortality. , 2011, International journal of cardiology.
[3] James D. Thomas,et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. , 2011, The American journal of cardiology.
[4] Hans L Hillege,et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction , 2010, Annals of medicine.
[5] M. Picard,et al. Galectin‐3, cardiac structure and function, and long‐term mortality in patients with acutely decompensated heart failure , 2010, European journal of heart failure.
[6] A. Wu,et al. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure. , 2010, Clinical biochemistry.
[7] H. Hillege,et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study , 2010, Clinical Research in Cardiology.
[8] Kenichi Watanabe,et al. A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy , 2010, Heart and Vessels.
[9] Yi-Lwun Ho,et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[10] N. Henderson,et al. The regulation of inflammation by galectin‐3 , 2009, Immunological reviews.
[11] O. Carretero,et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. , 2009, American journal of physiology. Heart and circulatory physiology.
[12] O. Carretero,et al. Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. , 2008, American journal of physiology. Heart and circulatory physiology.
[13] J. Iredale,et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. , 2008, The American journal of pathology.
[14] Fu-Tong Liu,et al. Role of galectin-3 in human pulmonary fibrosis. , 2007, Allergology international : official journal of the Japanese Society of Allergology.
[15] P. Ellinor,et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. , 2006, Journal of the American College of Cardiology.
[16] J. Iredale,et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[17] Yigal M. Pinto,et al. Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.
[18] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[19] M. Pfeffer,et al. Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. , 2003, Journal of the American College of Cardiology.
[20] H. Friess,et al. Galectin-1 and Galectin-3 in Chronic Pancreatitis , 2000, Laboratory Investigation.
[21] M. Alam,et al. Clinical predictors of heart failure in patients with first acute myocardial infarction. , 1999, American heart journal.
[22] J. Murabito,et al. Temporal trends in event rates after Q-wave myocardial infarction: the Framingham Heart Study. , 1999, Circulation.
[23] Jung‐Ta Chen,et al. Galectin‐3 expression is induced in cirrhotic liver and hepatocellular carcinoma , 1999, International journal of cancer.
[24] M. Kasper,et al. IMMUNOCYTOCHEMICAL EVIDENCE FOR A MODULATION OF GALECTIN 3 (Mac‐2), A CARBOHYDRATE BINDING PROTEIN, IN PULMONARY FIBROSIS , 1996, The Journal of pathology.